Presentation is loading. Please wait.

Presentation is loading. Please wait.

Updates From CROI 2019: Treatment of HIV and Its Complications

Published byΝαθαναήλ Γιαννόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Updates From CROI 2019: Treatment of HIV and Its Complications"— Presentation transcript:

1 Updates From CROI 2019: Treatment of HIV and Its Complications

2 Updates From CROI 2019: Treatment of HIV and Its Complications

3

4

5 CME Information

6 Nursing and Pharmacy Credits

7 Evaluations will be available in your IAS-USA “My Activities” page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

8 Grant Support for this Webinar

9 Navigating the Webinar

10 Poll 1

11 Poll 2

12 Poll 3

13 Updates From CROI 2019: Treatment of HIV and Its Complications

14 Financial Relationships With Commercial Entities

15 Learning Objectives

16 Pretest Question

17 Update from 2019 CROI

18

19 Possible cure of HIV infection

20 Possible cure of HIV-1 infection

21 Possible cure of HIV-1 infection

22 Possible cure of HIV-1 infection

23

24 HIV-1 Capsid inhibitor

25 HIV-1 Capsid inhibitor

26 HIV-1 Maturation inhibitor

27 HIV-1 Maturation inhibitor

28

29 RCT of Point of care viral load testing: STREAM study

30 Long acting injectable cabotegravir + rilpivirine

31 Long acting injectable cabotegravir + rilpivirine

32 Long acting injectable cabotegravir + rilpivirine

33 Long acting injectable cabotegravir + rilpivirine

34 Long acting injectable cabotegravir + rilpivirine

35 Long acting injectable cabotegravir + rilpivirine

36 Long acting injectable cabotegravir + rilpivirine

37 Long acting injectable cabotegravir + rilpivirine

38 Long acting injectable cabotegravir + rilpivirine

39 Long acting injectable cabotegravir + rilpivirine

40 PRO140 (CCR5 mAb) alone for maintenance therapy

41 Dolutegravir/lamivudine: target not detected

42 Archived NRTI resistance and response to InSTI +2 NRTI

43

44 TAF vs. TDF in women: Virologic responses

45 TAF vs. TDF in women: Bone outcomes

46 TAF vs. TDF in women: Renal outcomes

47 NICHD P1081: RAL vs. EFV for pregnant WLWH

48 NICHD P1081: RAL vs. EFV for pregnant WLWH

49 DolPHIN: DTG vs. EFV for pregnant WLWH

50 DolPHIN: DTG vs. EFV for pregnant WLWH

51 DolPHIN: DTG vs. EFV for pregnant WLWH

52 INSTI use during pregnancy

53 Levonorgestrol (LNG) implants and efavirenz

54 Quadrivalent HPV vaccine to improve response to LEEP treatment

55

56 Doxycycline vs. extended azithromycin for LGV proctitis

57 VACS: HIV and the risk of sudden cardiac death

58 VACS: HIV and the risk of sudden cardiac death

59 Opioid overdose deaths in PLWH

60 Opioid overdose deaths in PLWH

61 Integrase inhibitors and weight gain

62 Integrase inhibitors and weight gain

63 Weight gain after switch to integrase inhibitor

64 Weight Gain After Switch to INSTI-Based ART by Agent, Pre-Switch ART Class, and NRTI Backbone at Switch

65 Predictors of weight gain in an observational cohort

66 Predictors of weight gain in an observational cohort

67 HPTN 077: cabotegravir PrEP and weight gain

68 HPTN 077: cabotegravir and weight gain

69 Summary

70 Posttest Question

71 Question-and-Answer

72

73 Evaluations will be available in your IAS-USA “My Activities” page by 5 pm PT today. See the IAS–USA website for instructions on claiming CME, pharmacy, nursing, or pharmacotherapy credits, or a certificate of participation.

74 Final Poll

75

76

77 Sexual Health, HIV Prevention, and Primary Care in 2019

78

79

80

81 Thank You

Download ppt "Updates From CROI 2019: Treatment of HIV and Its Complications"

Similar presentations

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Jointly Sponsored by: and Clinical Context: HIV/AIDS in Practice Expert Commentary.

Jointly Sponsored by: and Clinical Context: HIV/AIDS in Practice Expert Commentary.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
11 HIV and contraception – complex issues for safe choice: the latest recommendations from the World Health Organization (WHO) Mary Lyn Gaffield, Sharon.

11 HIV and contraception – complex issues for safe choice: the latest recommendations from the World Health Organization (WHO) Mary Lyn Gaffield, Sharon.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.

Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.

ART Regimen Selection and Treatment Initiation for PMTCT Programs Lara Stabinski, MD, MPH Medical Officer Clinical Services S/GAC June 18, 2012.
Reproductive Health of People Living with HIV of People Living with HIV in Poland in Poland Tomasz Niemiec Other STD’s Neoplasmas Family Planning Demography.

Reproductive Health of People Living with HIV of People Living with HIV in Poland in Poland Tomasz Niemiec Other STD’s Neoplasmas Family Planning Demography.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.
Emerging comorbidities in the setting of long- term virological suppression Antonella Castagna San Raffaele Scientific Institute, Milan.

Emerging comorbidities in the setting of long- term virological suppression Antonella Castagna San Raffaele Scientific Institute, Milan.
Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Guidelines published as an update on 2003 guidelines. About 8-9 pages.

Guidelines published as an update on 2003 guidelines. About 8-9 pages. New data only Guidelines published as an update on 2003 guidelines. About 8-9 pages.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.

INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
Martin Fisher Foundation: 14 September 2015 www.i-Base.info Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.

Martin Fisher Foundation: 14 September Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.
Joel E. Gallant, MD, MPH Medical Director, Specialty Services Southwest CARE Center Santa Fe, New Mexico State-of-the-ART in Antiretroviral Management.

Joel E. Gallant, MD, MPH Medical Director, Specialty Services Southwest CARE Center Santa Fe, New Mexico State-of-the-ART in Antiretroviral Management.
Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI438011 Study  TAF (TFV prodrug) –Study 292-0102 –Study 299-0102  Doravirine.

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI Study  TAF (TFV prodrug) –Study –Study  Doravirine.
Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,

Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,
Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama at Birmingham Birmingham, Alabama Cases From the Clinic(ians):

Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama at Birmingham Birmingham, Alabama Cases From the Clinic(ians):
NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.

NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.
Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati,

Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati,

Similar presentations

Ads by Google